I'm LongbridgeAI, I can summarize articles.JOINNshares surged over 7% following a profit forecast indicating interim net profit could jump up to 13.77x year-on-year, reaching RMB900 million. The company attributes this growth to rising biological asset prices and natural appreciation. While laboratory operations remain stable, revenue saw slight growth due to past industry competition, with gross margins still awaiting recovery.
JOINN (06127.HK) +2.460 (+11.081%) Short selling $11.83M; Ratio 6.474% opened 12.61% higher today and once peaked at HKD25. The stock now trades at HKD23.86, up 7.48%, with turnover of 2.9442 million shares involving HKD71.1382 million.
The company issued a profit forecast expecting interim operating revenue for the period ending end-Jun this year to range from approximately RMB669 million to RMB739 million, representing a YoY increase of approximately 0% to 10.5%; net profit is expected to range from approximately RMB600 million to RMB900 million, representing a YoY increase of approximately 884.9% to 1,377.4%; net profit excluding non-recurring gains and losses is expected to range from approximately RMB561 million to RMB842 million, representing a YoY increase of approximately 2,334.2% to 3,551.3%.
JOINN said that during the period, rising market prices of biological assets combined with the company's own natural growth appreciation drove positive changes in fair value under dual factors, making a positive contribution to the company's results. The company's laboratories continued to maintain good and stable operations. Although the industry as a whole is recovering, revenue only recorded slight growth during the period due to the lagged impact of intense industry competition in the earlier stage, while gross margin levels still await recovery. (sl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-14 16:25.)